Abstract Purpose Pittsburgh Compound-B (11C-PiB) and 18F-florbetapir are amyloid-β (Aβ)
positron emission tomography (PET) radiotracers that have been used as endpoints in …

Background A validated PET amyloid tracer could improve diagnosis and management of
dementing disorders. We will report the results for the first Phase III multicenter validation …

Background Over the last decade, an increasing number of studies have been published on
the use of amyloid-β (Aβ) PET imaging with different 18 F-radiopharmaceuticals for clinical …

PET imaging of amyloid-β (Aβ) has become an important component of Alzheimer disease
diagnosis. 11C-Pittsburgh compound B (11C-PiB) and analogs bind to fibrillar Aβ. However …

Background We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ)
immunoglobulin (Ig) G4 monoclonal antibody, on biomarkers of amyloid pathology …

Objective: To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using
11C-Pittsburgh compound B (11C-PiB)-PET. Methods: Two phase 3 clinical trials, 1 each in …

Lecanemab is a humanized IgG1 monoclonal antibody that targets protofibrils, a species of
soluble aggregated amyloidbeta (Aβ). The drug was approved by the US Food and Drug …

11C-Pittsburgh compound B (11C-PiB) and 18F-florbetapir amyloid-β (Aβ) PET radioligands
have had a substantial impact on Alzheimer disease research. Although there is evidence …

Background Amyloid-β (Aβ) plaque formation is a hallmark of Alzheimer's disease (AD) and
precedes the onset of dementia. Aβ imaging should allow earlier diagnosis, but clinical …

In Alzheimer's disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a
series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction …